• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Protagonist Therapeutics, Inc. - Common Stock (NQ:PTGX)

128.75 -7.80 (-5.71%)
Delayed Quote Updated: 4:00 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 886,813
Open 136.16
Bid (Size) 121.00 (100)
Ask (Size) 148.00 (100)
Prev. Close 136.55
Today's Range 126.39 - 136.56
52wk Range 73.08 - 160.81
Shares Outstanding 62,577,897
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Protagonist Therapeutics (NASDAQ:PTGX): Strong Growth Meets Constructive Technical Setup ↗
October 16, 2026
Via Chartmill
Protagonist Therapeutics (NASDAQ:PTGX): High Growth Momentum Meets Breakout Setup ↗
October 08, 2026
Via Chartmill

Performance

52-Week Range 19.9% below 52-week high
128.75
73.0852W Low 160.8152W High
1 Week 15.4% below 1-week high
126.391W Low 152.191W High

Protagonist Therapeutics, Inc. - Common Stock (PTGX) traded between $73.08 and $160.81 over the past 52 weeks and last traded at $128.75, 19.9% below its 52-week high. Over the past week it ranged between $126.39 and $152.19.

Past 12 Months
-11.1%
-9.9%
-8.6%
+21.5%
+47.7%
+70.0%
1W -$16.13
1M -$14.09
3M -$12.16
6M +$22.77
YTD +$41.57
1Y +$53.02

PTGX was +70.0% over the past year, +21.5% over six months, +47.7% year to date, -11.1% in the last week.

12 Months vs Market
PTGX
+70.0%
DIA
+13.0%
SPY
+15.5%
QQQ
+18.3%
IWM
+10.4%

Over the past 12 months PTGX returned +70.0% versus DIA (Dow) +13.0%, SPY (S&P 500) +15.5%, QQQ (Nasdaq 100) +18.3% and IWM (Russell 2000) +10.4%.

Volume & Liquidity 1.40× 3-mo avg
Today 886,813 3-mo avg 634.5K
1W
840.8K
1M
848.6K
3M
634.5K
6M
675.8K
YTD
722.2K
1Y
767.9K

PTGX most recently traded 886,813 shares against a 3-month average daily volume of 634.5K.

More News

Read More
Protagonist Therapeutics (NASDAQ:PTGX) Combines Strong Growth With a High-Quality Technical Setup ↗
September 23, 2026
Via Chartmill
Protagonist Therapeutics (NASDAQ:PTGX) Combines High Growth Momentum With a Breakout Setup ↗
September 15, 2026
Via Chartmill
News headline image
Protagonist Therapeutics Announces $300 Million Share Repurchase Program
September 08, 2026
From Protagonist Therapeutics
Via ACCESS Newswire
News headline image
Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026
September 02, 2026
From Protagonist Therapeutics
Via ACCESS Newswire
News headline image
Protagonist Wins FDA Approval for MIMRYLO in Rare Blood Cancer Treatment ↗
August 31, 2026
Via MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Combines Strong Growth with a Promising Technical Setup ↗
August 28, 2026
Via Chartmill
Protagonist Therapeutics (NASDAQ:PTGX) Screens as an Affordable Growth Opportunity ↗
August 15, 2026
Via Chartmill
Protagonist Therapeutics (NASDAQ:PTGX) Passes Minervini Trend Template and High-Growth Screen ↗
August 13, 2026
Via Chartmill
News headline image
Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch. ↗
August 31, 2026
Via The Motley Fool
News headline image
Protagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO(TM) (rusfertide) for Polycythemia Vera
August 28, 2026
From Protagonist Therapeutics
Via ACCESS Newswire
News headline image
Protagonist Therapeutics Reports Granting of Inducement Awards
August 18, 2026
From Protagonist Therapeutics
Via ACCESS Newswire
News headline image
Protagonist Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 05, 2026
From Protagonist Therapeutics
Via ACCESS Newswire
Protagonist Therapeutics (NASDAQ:PTGX): A High Growth Momentum Stock Meeting the Mark Minervini Technical Setup ↗
July 22, 2026
Via Chartmill
Protagonist Therapeutics (NASDAQ:PTGX) Shows Technical Strength and High Growth Momentum ↗
June 13, 2026
Via Chartmill
News headline image
Protagonist Therapeutics Reports Granting of Inducement Awards
August 04, 2026
From Protagonist Therapeutics
Via ACCESS Newswire
News headline image
Protagonist Therapeutics Reports Granting of Inducement Awards
July 16, 2026
From Protagonist Therapeutics
Via ACCESS Newswire
News headline image
Protagonist Therapeutics Reports Granting of Inducement Awards
July 01, 2026
From Protagonist Therapeutics
Via ACCESS Newswire
News headline image
Protagonist Therapeutics Reports Granting of Inducement Awards
June 16, 2026
From Protagonist Therapeutics
Via ACCESS Newswire
News headline image
Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association Congress
June 01, 2026
Via ACCESS Newswire
News headline image
Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800% ↗
May 29, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More ↗
May 29, 2026
Via The Motley Fool
News headline image
Protagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026
May 28, 2026
Via ACCESS Newswire
News headline image
Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval ↗
May 18, 2026
Via The Motley Fool
Topics Regulatory Compliance

Frequently Asked Questions

Is Protagonist Therapeutics, Inc. - Common Stock publicly traded?
Yes, Protagonist Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Protagonist Therapeutics, Inc. - Common Stock trade on?
Protagonist Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Protagonist Therapeutics, Inc. - Common Stock?
The ticker symbol for Protagonist Therapeutics, Inc. - Common Stock is PTGX on the Nasdaq Stock Market
What is the current price of Protagonist Therapeutics, Inc. - Common Stock?
The current price of Protagonist Therapeutics, Inc. - Common Stock is 128.75
When was Protagonist Therapeutics, Inc. - Common Stock last traded?
The last trade of Protagonist Therapeutics, Inc. - Common Stock was at 10/16/26 04:00 PM ET
What is the market capitalization of Protagonist Therapeutics, Inc. - Common Stock?
The market capitalization of Protagonist Therapeutics, Inc. - Common Stock is 8.06B
How many shares of Protagonist Therapeutics, Inc. - Common Stock are outstanding?
Protagonist Therapeutics, Inc. - Common Stock has 8B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap